TIDMPRTC
PureTech Health PLC
13 December 2017
13 December 2017
PureTech Health plc
PureTech's Vedanta Biosciences Granted Four New US Patents
Expanding Coverage for Compositions and Methods of Use for
Medicines Based on Microbiome-Derived Bacterial Consortia
PureTech Health plc (LSE: PRTC), an advanced, clinical-stage
biopharmaceutical company, is pleased to note that Vedanta
Biosciences, an affiliate of PureTech Health, today announced that
the United States Patent and Trademark Office (USPTO) has issued
four new patents to Vedanta Biosciences, which broadly cover
compositions of matter and methods of use for therapeutic products,
including mixtures of bacterial strains and spore-forming fractions
based on beneficial bacteria. The new patent issuances broaden the
coverage for several programmes in Vedanta's clinical-stage
pipeline, including the lead investigational product candidate,
VE303, and further strengthen Vedanta's leading intellectual
property position in the microbiome field.
Bharatt Chowrira, President and Chief of Business and Strategy
at PureTech Health, said: "These foundational microbiome patents
add to the growing intellectual property portfolio across our
PureTech Health pipeline of programmes covered by over 400 issued
and pending patents in major markets."
The full text of the announcement from Vedanta Biosciences is as
follows:
Vedanta Biosciences Granted Four New US Patents Expanding
Coverage for Compositions and Methods of Use for Therapeutics Based
on Microbiome-Derived Bacterial Consortia
CAMBRIDGE, Massachusetts, December 13, 2017- Vedanta
Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing
a new category of therapies for immune-mediated and infectious
diseases based on rationally defined consortium of human
microbiome-derived bacteria, today announced that the United States
Patent and Trademark Office (USPTO) has issued four new patents, US
9,801,933, US 9,808,519, US 9,827,276, and US 9,833,483. The new
patents broadly cover pharmaceutical compositions including
Clostridium bacterial strains and methods of use for therapeutic
products, including consortia of bacterial strains and
spore-forming fractions based on beneficial bacteria. The newly
issued patents are exclusively licensed to Vedanta under an
agreement with the University of Tokyo and provide coverage through
at least 2031. These issuances further strengthen Vedanta's leading
intellectual property position in the microbiome field, which
includes previous issuances US 9,415,079, US 9,421,230, US
9,433,652, US 9,642,882, US 9,662,381, EP2575835, JP5592958,
JP5853063, and JP6115971.
"The expansion of our intellectual property estate further
establishes Vedanta's leading IP position in the microbiome field
and provides further recognition of the ground-breaking work of
Vedanta Biosciences co-founder Dr Kenya Honda," said Bernat Olle,
PhD, Chief Executive Officer of Vedanta Biosciences. "We believe
The University of Tokyo patents provide Vedanta a significant
competitive advantage in the microbiome field in the development of
drugs based on bacterial consortia."
The new US patent issuances broaden the coverage for several
programs in Vedanta's clinical-stage pipeline, including the lead
investigational product candidate, VE303, which has just entered
the clinic for the treatment of recurrent C. difficile infections.
The issuances also provide an additional layer of support for
Vedanta's therapeutic candidates for the treatment of Inflammatory
Bowel Disease (IBD), Food Allergy, and other autoimmune and
infectious diseases.
About Vedanta Biosciences
Vedanta Biosciences is pioneering development of a new category
of therapies for immune-mediated and infectious diseases based on
rationally defined consortia of bacteria derived from the human
microbiome. An affiliate of PureTech Health (PureTech Health plc,
PRTC.L), Vedanta's founding team includes a group of world-renowned
experts in immunology and microbiology. Vedanta Biosciences is a
leader in the microbiome field with capabilities and deep expertise
to discover, develop and manufacture drugs based on live bacterial
consortia. The Company's facilities include integrated
manufacturing operations providing cGMP-compliant manufacturing of
rationally-defined bacterial consortia in powder form. Leveraging
its proprietary technology platform and the expertise of its team
of scientific co-founders, Vedanta Biosciences has isolated and
maintains what we believe to be the largest collection of human
microbiome-associated bacterial strains and has characterised, in
collaborations with leading experts, how the immune system
recognises and responds to these microbes. This pioneering work has
led to the identification of human commensal bacteria that induce a
range of immune responses - including induction of regulatory T
cells, CD8+ T cells, and Th17 cells, among others - as well as the
characterisation of novel molecular mechanisms of microbial-host
communication. These advances have been published in leading
peer-reviewed journals including Science (multiple), Nature
(multiple), Cell and Nature Immunology. Vedanta Biosciences has
harnessed these biological insights, its proprietary library of
microbiome-derived bacterial strains, as well as data from clinical
translational collaborations, to generate a pipeline of programmes
addressing infectious diseases, autoimmune diseases, inflammation
and immune-oncology indications.
Vedanta Biosciences' scientific co-founders have pioneered the
fields of innate immunity, Th17 and regulatory T cell biology, and
include Dr Ruslan Medzhitov (Professor of Immunobiology at Yale),
Dr Alexander Rudensky (tri-institutional Professor at the Memorial
Sloan-Kettering Institute, the Rockefeller University and Cornell
University), Dr Dan Littman (Professor of Molecular Immunology at
NYU), Dr Brett Finlay (Professor at the University of British
Columbia) and Dr Kenya Honda (Professor, Keio University School of
Medicine). Vedanta is backed by Seventure, Invesco Asset
Management, and Rock Springs Capital and has collaborations with
leading institutions including Janssen Biotech, Inc., NYU Langone
Health and its Perlmutter Cancer Center, Stanford University School
of Medicine, Leiden University Medical Center, University of Tokyo,
Keio University, RIKEN, and the University of South Alabama
Mitchell Cancer Institute.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is an advanced,
clinical-stage biopharmaceutical company developing novel medicines
targeting serious diseases that result from dysfunctions in the
nervous, immune, and gastrointestinal systems (brain-immune-gut or
the "BIG" axis), which together represent the adaptive human
systems. PureTech Health is at the forefront of understanding and
addressing the biological processes and crosstalk associated with
the BIG axis. By harnessing this emerging field of human biology,
the Company is pioneering new categories of medicine with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies that includes two pivotal stage programmes, multiple
human proof-of-concept studies and a number of early clinical and
pre-clinical programmes. PureTech's rich research and development
pipeline has been advanced in collaboration with some of the
world's leading scientific experts, who along with PureTech's team
of biopharma pioneers, entrepreneurs and seasoned Board, identify,
invent, and clinically de-risk new medicines. With this experienced
team pursuing cutting edge science, PureTech Health is building the
biopharma company of the future focused on improving and extending
the lives of people with serious disease. For more information,
visit www.puretechhealth.com or connect with us on Twitter
@puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to
PureTech's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither PureTech Health nor any other party intends to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech Health FTI Consulting
Allison Mead Talbot Ben Atwell, Rob
+1 617 651 3156 Winder
amt@puretechhealth.com +44 (0) 20 3727
1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAXLLLFDLFZFBE
(END) Dow Jones Newswires
December 13, 2017 02:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024